XML 370 R43.htm IDEA: XBRL DOCUMENT
v3.26.1

Investments accounted for using the equity method (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Investments accounted for using the equity method |
Summary of development of the entity's equity method investment | The following table summarizes the development of the investments in associates during year 2025:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Centauri | ​ | ​ | ​ | ​
​ | ​ | Therapeutics | ​ | Insignificant | ​ | ​
in k€ | ​ ​ ​ | Ltd | ​ ​ ​ | investments | ​ ​ ​ | Total
Balance at January 1, 2025 | ​ | 1,264 | ​ | 874 | ​ | 2,138
Investment | ​ | 3,576 | ​ | — | ​ | 3,576
Share of profit/(loss) in associate | ​ | (634) | ​ | (451) | ​ | (1,085)
Impairment | ​ | — | ​ | — | ​ | —
Dividends earned, Divestment or Reclassification |  | — | ​ | — | ​ | —
Balance at December 31, 2025 |  | 4,206 | ​ | 423 | ​ | 4,629
​ The following table provides an overview of the development of the investments in 2024: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | ​ | ​ ​ ​ | Centauri | ​ ​ ​ | ​ | ​ | Quantro | ​ | Topas | ​ | ​ | ​ ​ ​ | ​ ​ ​
​ | ​ | Autobahn | ​ | Therapeutics | ​ | EIR | ​ | Therapeutics | ​ | Therapeutics | ​ | Insignificant | ​ | ​
in k€ | ​ ​ ​ | Labs LLC | ​ ​ ​ | Ltd. | ​ ​ ​ | Biotherapies | ​ | GmbH | ​ ​ ​ | GmbH | ​ ​ ​ | investments | ​ ​ ​ | Total
Balance at January 1, 2024 | ​ | — | ​ | 2,179 | ​ | — | ​ | 892 | ​ | — | ​ | — |  | 3,071
Investment | ​ | 1,378 | ​ | — | ​ | 1,022 | ​ | — | ​ | 977 | ​ | 2 | ​ | 3,379
Share of profit/(loss) in associate |  | (1,378) | ​ | (916) | ​ | (149) | ​ | (892) | ​ | (977) | ​ | — | ​ | (4,312)
Impairment |  | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Dividends earned, Divestment or Reclassification | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — |  | —
Balance at December 31, 2024 | ​ | — | ​ | 1,264 | ​ | 873 | ​ | — | ​ | — | ​ | 2 |  | 2,138
Schedule of financial information of significant investments | Further financial information on the significant investments accounted for using the equity method is presented below: ​ 2025 ​
​ | ​ | ​
​ | ​ | Centauri
​ | ​ | Therapeutics
in k€ | ​ ​ ​ | Ltd
Current assets |  | 14,127
Non-current assets |  | 239
Current liabilities |  | 233
Non-current liabilities |  | —
Revenues from Jan 1 to Dec 31 | ​ | 4,837
Net income (loss) Jan 1 to Dec 31 |  | (3,915)
​ 2024 ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | ​ ​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Centauri | ​ | Dark Blue | ​ | ​ | ​ | Quantro | ​ | Topas
​ | ​ | Therapeutics | ​ | Therapeutics | ​ | EIR | ​ | Therapeutics | ​ | Therapeutics
in k€ | ​ ​ ​ | Ltd. | ​ | Ltd. | ​ | Biotherapies | ​ ​ ​ | GmbH | ​ ​ ​ | GmbH
Current assets | ​ | 383 | ​ | 291 | ​ | 634 | ​ | 1,121 | ​ | 7,560
Non-current assets |  | 299 | ​ | 9,047 | ​ | 1,752 |  | 549 |  | 972
Current liabilities |  | 245 | ​ | 981 | ​ | 187 |  | 2,072 |  | 548
Non-current liabilities |  | — | ​ | — | ​ | 2 |  | 4,325 |  | —
Revenues from Jan 1 to Dec 31 | ​ | 1 | ​ | — | ​ | — | ​ | 1,294 | ​ | —
Net income (loss) Jan 1 to Dec 31 |  | (4,483) | ​ | (3,115) | ​ | (167) |  | (3,974) |  | (9,418)
​

X
- Definition Disclosure of interests in associates and joint ventures + References No definition available. + Details
Name: | evo_DisclosureOfInterestsInAssociatesAndJointVenturesTextBlock
Namespace Prefix: | evo_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of developments in equity method investments. + References No definition available. + Details
Name: | evo_ScheduleOfDevelopmentsOfEquityMethodInvestmentsTableTextBlock
Namespace Prefix: | evo_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration